Document:

Exhibit 10.1

 

[JAGUAR LETTERHEAD]

 

July 31, 2017

 

Re:                                 Reset Offer of Common Stock Purchase Warrants

 

To Whom It May Concern:

 

Jaguar Animal Health, Inc., a Delaware corporation (the “Company”), is pleased to offer to you the opportunity to reprice the exercise of all of the Common Stock purchase warrants set forth on Annex I attached hereto (collectively, the “Reprice Warrants”) currently held by you (the “Holder”). The shares underlying the Reprice Warrants (“Warrant Shares”) have been registered for resale pursuant to a registration statement on Form S-1 (File No. 333-214956) (the “Registration Statement”). The Registration Statement is currently effective and, upon exercise of the Reprice Warrants pursuant to this letter agreement, will be effective for the issuance or resale, as the case may be, of the Warrant Shares. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Securities Purchase Agreement, dated as of November 22, 2016, by and among the Company and the signatories thereto (the “Purchase Agreement”).

 

In consideration for exercising in some or all of the Reprice Warrants held by you (the “Warrant Exercise”), the Company hereby offers you a reduced exercise price of the Reprice Warrants as follows: $0.40 for all Series C Warrants. Notwithstanding anything herein to the contrary, in the event the Warrant Exercise would otherwise cause the Holder to exceed the beneficial ownership limitations (“Beneficial Ownership Limitation”) in the Reprice Warrants, the Company shall only issue such number of Warrant Shares to the Holder that would not cause such Holder to exceed the maximum number of Warrant Shares permitted thereunder with the balance to be held in abeyance until notice from such Holder that the balance (or portion thereof) may be issued in compliance with such limitations.

 

Expressly subject to the paragraph immediately following this paragraph below, Holder may accept this offer by signing this letter below, with such acceptance constituting Holder’s exercise of some or all of the Reprice Warrants for an aggregate exercise price as set forth on the Holder’s signature page hereto (the “Warrants Exercise Price”) on or before 8:00 a.m. Eastern Time on July 31, 2017 (the “Outside Exercise Time”). For the avoidance of doubt, to the extent that the Holder does not exercise all of such Holder’s Warrants issued pursuant to the Purchase Agreement on or prior to the Outside Exercise Time, all of the original terms and provisions of such Warrants, including the original exercise prices thereunder, shall remain in full force and effect and the Holder shall have no right to exercise the Warrants for the reduced exercise prices stated herein.

 

Additionally, the Company agrees to the representations, warranties and covenants set forth on Annex A attached hereto.

 

From the date hereof until ten (10) Trading Days after the date hereof, neither the Company nor any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents. Notwithstanding the foregoing, this provision shall not apply in respect of any Common Stock or Common Stock Equivalents to be issued in connection with: (i) the previously announced acquisition of Napo Pharmaceuticals, Inc., or (ii) the Jaguar Animal Health, Inc. 2014 Stock Incentive Plan.

 

 

If this offer is accepted and the transaction documents are executed on or before the Outside Exercise Time, then on or before 9:00 a.m. Eastern Time on July 31, 2017, the Company shall file a Current Report on Form 8-K with the Securities and Exchange Commission disclosing all material terms of the transactions  contemplated hereunder. The Company shall also file an amendment to the prospectus supplement to the Registration Statement disclosing the reduced exercise price of the Reprice Warrants within two (2) Trading Days. The Company represents, warrants and covenants that, upon acceptance of this offer, the shares underlying the Reprice Warrants shall be issued free of any legends or restrictions on resale by Holder and all of the Warrant Shares shall be delivered electronically through the Depository Trust Company within one (1) Business Day of the date the Company receives the Warrants Exercise Price (or, with respect to shares that would otherwise be in excess of the Beneficial Ownership Limitation, within two (2) Business Days of the date the Company is notified by Holder that its ownership is less than the Beneficial Ownership Limitation). The terms of the Reprice Warrants, including but not limited to the obligations to deliver the Warrant Shares, shall otherwise remain in effect as if the acceptance of this offer were a formal Notice of Exercise (including but not limited to any liquidated damages and compensation in the event of late delivery of the Warrant Shares).

 

The Company acknowledges and agrees that the obligations of the Holders under this letter agreement are several and not joint with the obligations of any other holder of any other holders of Common Stock Purchase Warrants of the Company (each, an “Other Holder”) under any other agreement related to the exercise of such warrants (“Other Warrant Exercise Agreement”), and the Holder shall not be responsible in any way for the performance of the obligations of any Other Holder or under any such Other Warrant Exercise Agreement. Nothing contained in this letter agreement, and no action taken by the Holders pursuant hereto, shall be deemed to constitute the Holders and the Other Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Holders and the Other Holders are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this letter agreement and the Company acknowledges that the Holders and the Other Holders are not acting in concert or as a group with respect to such obligations or the transactions contemplated by this letter agreement or any Other Warrant Exercise Agreement. The Company and the Holders confirm that the Holders have independently participated in the negotiation of the transactions contemplated hereby with the advice of its own counsel and advisors. The Holders shall be entitled to independently protect and enforce their rights, including, without limitation, the rights arising out of this letter agreement, and it shall not be necessary for any Other Holder to be joined as an additional party in any proceeding for such purpose.

 

The Company hereby represents and warrants as of the date hereof and covenants and agrees from and after the date hereof that none of the terms offered to any Other Holder with respect to any Other Warrant Exercise Agreement (or any amendment, modification or waiver thereof), is or will be more favorable to such Other Holder than those of the Holders and this letter agreement. If, and whenever on or after the date hereof, the Company enters into an Other Warrant Exercise Agreement, then (i) the Company shall provide notice thereof to the Holders promptly following the occurrence thereof and (ii) the terms and conditions of this letter agreement shall be, without any further action by the Holders or the Company, automatically amended and modified in an economically and legally equivalent manner such that the Holder shall receive the benefit of the more favorable terms and/or conditions (as the case may be) set forth in such Other Warrant Exercise Agreement (including the issuance of additional Warrant Shares); provided  that upon written notice to the Company at any time the Holder may elect not to accept the benefit of any such amended or modified term or condition, in which event the term or condition contained in this letter agreement shall apply to the Holders as it was in effect immediately prior to such amendment or modification as if such amendment or modification never occurred with respect to the Holders. The provisions of this paragraph shall apply similarly and equally to each Other Warrant Exercise Agreement.

 

[Signature Pages Follow]

 

 

To accept this offer, Holder must counter execute this letter agreement and return the fully executed agreement to the Company at e-mail: lconte@jaguaranimalhealth.com, attn.: Lisa Conte, on or before 8:00 am Eastern Time on July 31, 2017.

 

 

	
 
    	
Sincerely yours,
    
	
 
    	
 
    	
 
    
	
 
    	
JAGUAR ANIMAL HEALTH, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name: 
    	
Lisa A. Conte
    
	
 
    	
Title:
    	
President and   Chief Executive Officer
    
				

 

	
Accepted and   Agreed to:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Name of Holder:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Signature   of Authorized Signatory of Holder:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Name of   Authorized Signatory:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Title of   Authorized Signatory:
    	
 
    	
 
    
	
 
    	
 
    
	
Repriced Warrant   Shares:
    	
 
    	
 
    
							

 

1.              Series C Warrants

 

a.              Number of Series C Warrants Exercised:

 

b.              Aggregate Exercise Price for Series C Warrants: $

 

 

Annex A

 

Representations, Warranties and Covenants of the Company. The Company hereby makes the following representations and warranties to the Holder:

 

(a)      Affirmation of Prior Representations, Warranties and Covenants. The Company hereby represents and warrants to the Holder that the Company’s representations and warranties as set forth in Section 3.1 and as set forth in covenants listed in Article IV of the Securities Purchase Agreement, dated as of November 22, 2016 (the “Purchase Agreement”), together with any updates in the Company’s SEC Reports subsequent to the Purchase Agreement, are true and correct as of the date hereof and have been fully performed as of the date hereof. Capitalized terms not otherwise defined in this Annex A shall have the meanings set forth in the Purchase Agreement. Additionally, the Company hereby represents and warrants to the Holder that as of July 26, 2017, there were 18,093,345 shares of common stock, par value $0.0001 per share, outstanding.

 

(b)      Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this letter agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection therewith. This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

 

(c)      No Conflicts. The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company’s certificate of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company in connection with, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or by which any property or asset of the Company is bound or affected; or (iii) subject to the Required Approvals (as defined in the Purchase Agreement), conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected, except, in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect (as defined in the Purchase Agreement).

 

(d)      Nasdaq Corporate Governance. The transactions contemplated under this letter agreement, comply with all rules of the Trading Market.

 

 

Annex I

 

1.              Up to an aggregate of 1,666,668 Series C Warrants.*

 

*  As defined in the Securities Purchase Agreement, dated as of November 22, 2016, by and among Jaguar Animal Health, Inc. and the purchasers signatory thereto.Exhibit

	
	
	CALL OPTION TERMINATION AGREEMENT 
dated as of June 29, 2017

	Between EZCORP, INC. and UBS AG, LONDON BRANCH

THIS CALL OPTION TERMINATION AGREEMENT (this “Agreement”) with respect to the Call Option Confirmations (as defined below) is made as of June 29, 2017, between EZCORP, Inc. (“Company”) and UBS AG, London Branch (“Dealer”).  
WHEREAS, Company issued $200,000,000 principal amount of 2.125% Cash Convertible Senior Notes due 2019 (the “Convertible Notes”), and another $30,000,000 principal amount of Convertible Notes in connection with the initial purchasers’ option to purchase additional Convertible Notes (the “Additional Notes”), in each case, pursuant to an Indenture dated as of June 23, 2014 between Company and Wells Fargo Bank, National Association, as trustee; 
WHEREAS, in connection with the pricing of the Convertible Notes, Company and Dealer entered into a Base Call Option Transaction (the “Base Call Option Transaction”) pursuant to a letter agreement re: Call Option Transaction dated as of June 17, 2014 confirming the terms of a call option transaction (as amended, modified, terminated or unwound from time to time, the “Base Call Option Confirmation”); 
WHEREAS, in connection with the Additional Notes, Company and Dealer entered into an Additional Call Option Transaction (the “Additional Call Option Transaction” and, together with the Base Call Option Transaction, the “Call Option Transactions”) pursuant to a letter agreement re: Additional Call Option Transaction dated as of June 27, 2014 confirming the terms of an additional call option transaction (as amended, modified, terminated or unwound from time to time, the “Additional Call Option Confirmation” and, together with the Base Call Option Confirmation, the “Call Option Confirmations”);
WHEREAS, in connection with a repurchase by Company of 35,000 Convertible Notes in $1,000 principal amount denominations (the “Notes Repurchase”, and such number of Convertible Notes in $1,000 principal amount denominations, the “Repurchase Number”), Company has requested a full termination of the Additional Call Option Transaction and partial termination of the Base Call Option Transaction;
NOW, THEREFORE, in consideration of their mutual covenants herein contained, the parties hereto, intending to be legally bound, hereby mutually covenant and agree as follows:
1.    Defined Terms.  Any capitalized term not otherwise defined herein shall have the meaning set forth for such term in the Call Option Confirmations.

2.    Termination and Amendment.  Notwithstanding anything to the contrary in the Call Option Confirmations, Company and Dealer agree that, effective on the date hereof, (i) the Additional Call Option Transaction shall automatically terminate and all of the respective rights and obligations of the parties under the Additional Call Option Confirmation shall be terminated, cancelled and extinguished and (ii) the Number of Options under the Base Call Option Transaction shall be reduced to 195,000, and in connection therewith Dealer shall be required to pay to Company the Cash Settlement Amount on the Payment Date pursuant to Sections 3 and 4 below. For the avoidance of doubt, the parties agree that the Notes Repurchase shall be disregarded for all purposes under the Call Option Transactions, and without limiting the foregoing, no Early Termination Date shall be deemed to occur with respect to any Call Option Transaction or any portion thereof on account of the Notes Repurchase.

3.    Procedures for Hedge Unwind.    On each Hedge Unwind Date (as defined below), Dealer (or an affiliate of Dealer), for the account of Dealer, shall unwind a portion of its hedge of the Options underlying the Call Option Transactions being terminated hereunder (the period of ten consecutive Scheduled Trading Days beginning on and including the Exchange Business Day following the Effective Date (as defined below, and such Exchange Business Day, the “Start Date”) being collectively referred to as the “Hedge Unwind Period” (subject to extension pursuant to the proviso in the immediately following sentence)).  A “Hedge Unwind Date” means the Start Date and each Scheduled Trading Day in the Hedge Unwind Period; provided, however, that if any such date is a Disrupted Day in whole, such date shall not constitute a Hedge Unwind Date, and an additional Hedge Unwind Date shall occur on the Scheduled Trading Day after the date that would otherwise be the final Hedge Unwind Date. 

4.    Payments and Deliveries.  On the third Scheduled Trading Day following the final Hedge Unwind Date or, if such day is not a Clearance System Business Day, on the next Clearance System Business Day immediately following such day (the “Payment Date”), Dealer shall pay to Company in immediately available funds cash in an amount equal to the Cash Settlement Amount.  The “Cash Settlement Amount” shall mean an amount in US Dollars determined by Dealer according to the table set forth in Schedule A attached hereto (using linear interpolation or commercially reasonable extrapolation by Dealer, as applicable, to determine the Cash Settlement Amount for any Average VWAP not specifically appearing in Schedule A).  “Average VWAP” means the arithmetic average of the VWAP Prices for each Hedge Unwind Date during the Hedge Unwind Period.  “VWAP Price” for any Scheduled Trading Day means the per Share volume-weighted average price as displayed under the heading “Bloomberg VWAP” on Bloomberg page EZPW <equity> AQR (or any successor thereto) in respect of the period from 9:30 am to 4:00 pm (New York City time) on such Scheduled Trading Day (or if such volume-weighted average price is unavailable, the market value of one Share on such Scheduled Trading Day for such time period, as determined by Dealer).  Notwithstanding the foregoing, if any Scheduled Trading Day in the Hedge Unwind Period is a Disrupted Day (in whole or in part), then the VWAP Price for such Scheduled Trading Day(s) shall be the volume-weighted average price per Share on such Scheduled Trading Day on the Exchange for such time period, as determined by Dealer based on such sources as it deems appropriate using a volume-weighted methodology, for the portion of such Scheduled Trading Day for which Dealer determines there is no Market Disruption Event with respect to the Shares (if any) and the number of Hedge Unwind Dates and the Cash Settlement Amount shall be adjusted by Dealer in its good faith, commercially reasonable discretion to account for such disruption and/or extension. 

5.    Effectiveness.  This Agreement, including the termination and amendment of the Call Option Confirmations as set forth herein, shall be effective upon the date (the “Effective Date”) that each of (i) Company’s offering of its 2.875% Convertible Senior Notes due 2024 and (ii) the Notes Repurchase has been consummated and settled.  If, for any reason, the Effective Date has not occurred on or prior to July 5, 2017, (i) this Agreement shall automatically terminate and all of the respective rights and obligations of Company and Dealer hereunder shall be cancelled, terminated and discharged and (ii) each party shall be released and discharged by the other party from, and agrees not to make any claim against the other party with respect to, any obligations or liabilities of the other party arising out of and to be performed in connection with this Agreement.

6.    Representations and Warranties of Company.  Company represents and warrants to Dealer (and agrees with Dealer in the case of Section 6(g)(ii)) on the date hereof that:

(a)  it has the power to execute this Agreement and any other documentation relating to this Agreement to which it is a party, to deliver this Agreement and to perform its obligations under this Agreement and has taken all necessary action to authorize such execution, delivery and performance;

(b)  such execution, delivery and performance do not violate or conflict with any law applicable to it, any provision of its constitutional documents, any order or judgment of any court or other agency of government applicable to it or any of its assets or any material contractual restriction binding on or affecting it or any of its assets;

(c)  all governmental and other consents that are required to have been obtained by it with respect to this Agreement have been obtained and are in full force and effect and all conditions of any such consents have been complied with; 

(d)  its obligations under this Agreement constitute its legal, valid and binding obligations, enforceable in accordance with their respective terms (subject to applicable bankruptcy, reorganization, insolvency, moratorium or similar laws affecting creditors’ rights generally and subject, as to enforceability, to equitable principles of general application (regardless of whether enforcement is sought in a proceeding in equity or at law)); 

(e) each of it and its affiliates is not in possession of any material nonpublic information regarding Company or the Shares; 

(f)  it is not entering into this Agreement to create actual or apparent trading activity in the Shares (or any security convertible into or exchangeable for the Shares), to raise or depress or otherwise manipulate the price of the Shares (or any security convertible into or exchangeable for the Shares), for the purpose of inducing the sale of the Shares (or any security convertible into or exchangeable for the Shares) by others or otherwise in violation of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), provided that Company makes no representation or warranty with respect to Dealer’s Hedge Position (or any other dealer’s hedge position in respect of derivatives relating to the Convertible Notes); and

(g)  (i) it is not on the date hereof, engaged in a distribution, as such term is used in Regulation M under the Exchange Act (“Regulation M”), of the Shares or any securities deemed “reference securities” (as defined in Regulation M) 

1

with respect to the Shares and (ii) it shall not engage in any such distribution during the period commencing on the date hereof and ending on the second Exchange Business Day immediately following the last day of the Hedge Unwind Period with respect to the Shares or such reference securities, unless it notifies Dealer, on the day immediately preceding the first day of the “restricted period” (as defined in Regulation M) of any such distribution, and of completion of such restricted period on the date such distribution is concluded; provided that, in connection with the notification with respect to the completion of the restricted period, it shall be deemed to repeat the representations contained in paragraphs (e) and (f) of this Section 6.                 

7.    Representations and Warranties of Dealer.  Dealer represents and warrants to Company on the date hereof that:

(a)  it has the power to execute this Agreement and any other documentation relating to this Agreement to which it is a party, to deliver this Agreement and to perform its obligations under this Agreement and has taken all necessary action to authorize such execution, delivery and performance;

(b)  such execution, delivery and performance do not violate or conflict with any law applicable to it, any provision of its constitutional documents, any order or judgment of any court or other agency of government applicable to it or any of its assets or any material contractual restriction binding on or affecting it or any of its assets;

(c)  all governmental and other consents that are required to have been obtained by it with respect to this Agreement have been obtained and are in full force and effect and all conditions of any such consents have been complied with; and

(d)  its obligations under this Agreement constitute its legal, valid and binding obligations, enforceable in accordance with their respective terms (subject to applicable bankruptcy, reorganization, insolvency, moratorium or similar laws affecting creditors’ rights generally and subject, as to enforceability, to equitable principles of general application (regardless of whether enforcement is sought in a proceeding in equity or at law)).
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
8.    Account for Payment to Company:

Bank:    Wells Fargo Bank, NA 
ABA#:    121000248 
Acct Name:    Texas EZPawn, LP 
Acct No.:    4159720622
Contact:    Karissa Sullivan
Phone No.:    512-314-2257
 
9.     Governing Law.  This Agreement and any dispute arising hereunder shall be governed by and construed in accordance with the laws of the State of New York (without reference to choice of law doctrine).
    
10.     Counterparts.  This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if all of the signatures thereto and hereto were upon the same instrument.

11.    No Reliance, etc.  Company confirms that it has relied on the advice of its own counsel and other advisors (to the extent it deems appropriate) with respect to any legal, tax, accounting, or regulatory consequences of this Agreement, that it has not relied on Dealer or its affiliates in any respect in connection therewith, and that it will not hold Dealer or its affiliates accountable for any such consequences.

12.    Designation by Dealer.  Notwithstanding any other provision in this Agreement to the contrary requiring or allowing Dealer to purchase, sell, receive or deliver any Shares or other securities to or from Company, Dealer may designate any of its affiliates to purchase, sell, receive or deliver such shares or other securities and otherwise to perform Dealer obligations in respect of the transactions contemplated by this Agreement and any such designee may assume such obligations.  Dealer shall be discharged of its obligations to Company to the extent of any such performance.

13.    No Setoff; No Collateral. Notwithstanding any provision of this Agreement or any other agreement between the parties to the contrary, the obligations of Company hereunder are not, and shall not be, secured by any collateral. Each party waives any and all rights it may have to set off obligations arising under this Agreement and the Transaction against other obligations between the parties, whether arising under any other agreement, applicable law or otherwise.

2

14.    No Other Changes.  Except as expressly set forth herein, all of the terms and conditions of the Base Call Option Confirmation shall remain in full force and effect and are hereby confirmed in all respects.

[Signature Page Follows]
    
    

3

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.

	
				
	UBS AG, London Branch

	

By:
	/s/ Michael O'Donovan

	 
	Name:  Michael O'Donovan
Title:  Authorized Signatory

	 

	

By:
	/s/ Brian Badentscher

	 
	Name:  Brian Badentscher
Title:  Authorized Signatory

	 

	UBS Securities LLC, as Agent for UBS AG, London Branch

	

By:
	/s/ Michael O'Donovan

	 
	Name:  Michael O'Donovan
Title:  Managing Director

	 

	

By:
	/s/ Brian Badentscher

	 
	Name:  Brian Badentscher
Title:  Authorized Signatory

	 

	

EZCORP, Inc.

	

By:
	/s/ Thomas H. Welch, Jr.

	 
	Name:  Thomas H. Welch, Jr.
Title:  Chief Legal Officer and Secretary
	 

[Signature Page to Call Option Termination Agreement]

Schedule A
The Cash Settlement Amount shall be determined by Dealer according to the table below.

	
		
	Average VWAP
	Cash Settlement Amount

	$7.00
	$113,941

	$7.25
	$133,132

	$7.50
	$154,380

	$7.75
	$177,795

	$8.00
	$203,422

	$8.25
	$231,403

	$8.50
	$261,658

	$8.75
	$294,372

	$9.00
	$329,560

Dealer may adjust the table above upon the occurrence of any event or condition that would have allowed Dealer to adjust the terms of the Call Option Transactions under the Call Option Confirmations.

A-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]